Powered by Roche & aMoon
Menu
Christian Paetzke is Head Roche Diagnostics Strategy & Partnering.
Christian joined Roche in April 2002 where he began his career in the Management Start Up program. He has held various positions with increasing responsibility such as Director of Roche Diagnostics Ireland, Senior Vice President Marketing & Sales Lab Diagnostics in Germany and General Manager Roche Diagnostics Brazil. Before assuming his current position in 2023, he was General Manager of Roche Diagnostics Germany (RDD), starting in 2018.
Christian holds a diploma in European Business Administration from Dublin City University Business School in Dublin, Ireland and from European School of Business in Reutlingen, Germany.
Palani Kumaresan, Head of Roche Diagnostics Solutions (RDS), assumed his current role in November 2023.
Prior to that Palani served as Head of Research & Development Roche Diagnostics Solutions (RDS). Palani began his career with Roche in Roche Molecular Diagnostics (RMD) Pleasanton as Business Development Manager in 2010. He has held a variety of leadership roles with increasing responsibility including Head of Strategic Projects Office Roche Applied Science Penzberg, Business Director Core Lab and Critical Care Roche Diagnostics Sweden and General Manager Roche Diagnostics Central America and Caribbean. Prior to his current role, he served as Lifecycle Leader Infectious Diseases, Oncology and Endocrinology. Palani has a Ph.D. in the area of applied biochemistry and a Master of Science in engineering from the University of California, Berkeley.
Moritz Hartmann is Head of Roche Information Solution (RIS), which focuses on delivering data-driven solutions that empower healthcare professionals and patients to make insights-based decisions. Connecting the lab, care and home settings, these innovative digital solutions help unlock digital ecosystems across the care continuum for financial, operational, and clinical insights that drive personalized healthcare for patients around the globe.
Moritz started his career in the tourism industry developing online travel booking engines. He joined Roche in 2005 and since, has successfully led large and diverse organisations and teams across different regions and divisions while driving innovative digitisation projects and partnerships. Moritz was appointed Head of the newly created Roche Information Solutions (RIS) in May 2021.
A German native, Moritz holds degrees in Controlling and Finance as well as Marketing and International Management and an MBA from the Northwestern University – Kellogg School of Management.
Dr. Yair Schindel is the Co-Founder & Managing Partner of aMoon.
As a healthcare entrepreneur, investor, and physician with vast experience in the field, Yair established aMoon in 2017.
Before launching aMoon, Yair served as the founding CEO of Digital Israel, the State’s National Digital Bureau to accelerate digital transformation and stimulate economic growth on a national level. Prior to Digital Israel, Yair was the CEO of Startup Nation Central, a nonprofit organization that supports Israeli innovation. In 2010, Yair co-founded and served as CEO and board member of MAOZ, an NGO that trains and connects Israel’s most promising future leaders to promote social change initiatives and strengthen Israel’s socioeconomic resilience.
Yair is the Co-founder and Chairman of the non-profit organization The 8400 Health Network, which is committed to building a national HealthTech growth engine through a coalition of public, private, and nonprofit sector leaders.
In the private sector, Yair served as an executive, investor, board member, or advisory board member in several healthcare startups.
Yair earned his BSc and MD degrees at Ben-Gurion University’s Goldman Medical School and his MBA at the Harvard Business School. He currently serves on the Health Care Advisory Board at HBS. Prior to business school, Yair was the Chief Medical Officer for the Israeli Navy Seals, also known as “Shayetet 13.”
Bryn gained his BSc and PhD in pharmacology from the University of Bristol, UK. Following post-doctoral work in neuropharmacology, he joined Organon as Senior Scientist in 1996. A number of roles followed with Zeneca and AstraZeneca before he joined Roche in Basel in 2006 to head up research informatics and data science. In his current role as Global Head of Data & Analytics within Roche Diagnostics, Bryn’s accountabilities include data strategy and engineering, data science, data governance, information and digital solutions.
Beyond Roche, Bryn is a Visiting Professor at the University of Bristol and a Visiting Fellow at the University of Oxford, with interests in digital health, AI and machine learning, systems biology and scientific software development. He is an Associated Faculty member with the University of Frankfurt Big Data Lab and lectures in medical informatics at the University of Applied Sciences, NW Switzerland.
He is a member of several advisory boards including the University of Oxford Dept of Statistics and SABS Centre for Doctoral Training, the Microsoft Research/University of Trento Center for Computational and Systems Biology, University of Edinburgh School of Informatics, RoX Health and Z-Inspection.
Bryn is a non-executive director on the board of Deepmatter.
Matthias joined Roche Diagnostics in 1993 and has held various positions in technology assessment, research and product development.
In his current role as Chief Technology Officer and Chapter Head Technology and Science, he leads a team for scouting and assessing platform technologies for future diagnostics products, and provides input for business and strategy planning with insights on technology roadmaps. He is very passionate about the opportunities for improving care for patients through advancements in IVD and data driven insights and bringing care closer to the patient.
Matthias holds a PhD in Medical Physics from University College London, U.K. and received his M.Sc. Degree in Physics from Ludwig Maximilians Universität in Munich, Germany.
David Evans is an Investment Director at the Roche Venture Fund and brings over 20 years’ experience in the healthcare and pharmaceutical industries in investing, operations, and research. Before joining the Roche Venture Fund, David was in Roche Pharma where he led the global data sciences team supporting the neuroscience & rare diseases pipeline. Earlier in his career, David worked at Bristol Myers Squibb and Eli Lilly at global and affiliate levels and, prior to joining the pharmaceutical industry, at the World Bank, with Médecins Sans Frontières, and in clinical medicine. David holds an MBBS from the University of Sydney and a PhD in clinical epidemiology from the Université Pierre et Marie Curie, Paris.
Chapter Area Lead R&D Research and Early Development, Roche Diagnostics Solutions
Tom received his B.S. in Chemistry from the University of Michigan and a Ph.D. in Molecular Toxicology from the University of Wisconsin. Tom was an early employee of NimbleGen Systems, which was acquired by Roche in 2007.
Since then, Tom has held various R&D leadership positions in Roche Diagnostics. He has led teams that have conceived, developed and commercialized several important novel genomics technologies, including whole genome sequencing methods, hybrid capture for targeted sequencing, whole exome sequencing, and whole proteome peptide arrays.
Tom is currently Chapter Area Lead R&D Research and Early Development, leading the development of system, workflow, and assay technologies.
Okan Ekinci is Head of Marketing & Innovation for Roche Information Solution (RIS). RIS focuses on delivering data-driven solutions that empower healthcare professionals and patients to make insights-based decisions. Connecting the lab, care and home settings, these innovative digital solutions help unlock digital ecosystems across the care continuum for financial, operational, and clinical insights that drive personalized healthcare for patients around the globe.
With his organization, Okan is redefining the way how digital health products in RIS are designed, validated, implemented, and marketed with the aim to generate exceptional value for customers and patients.
Okan joined Roche in 2018 in Diagnostics Information Solutions to build and lead the new Medical & Scientific Affairs function.
Before joining Roche, he was Global Head & Vice President of the Healthcare Consulting business at Siemens Healthineers, developing and offering IT-enabled transformation and clinical consulting services. Prior to that, he established the Global Medical Office of Healthineers and served as its first CMO, across imaging, diagnostics and healthcare IT. Okan spent eight out of his 20+ years of experience in the healthcare sector in clinical practice in cardiology.
Okan holds an MBA from the European School of Management and Technology, Berlin, an MD from the University of Mainz, Germany, and is adjunct professor of medicine at the University College Dublin, Ireland.
Ruedi Stoffel assumed the role of Head Partnering Network Roche Diagnostics Solutions in 2021. Ruedi brings extensive Strategy & Business Development experience gained through various divisional, global and local Business Development roles at Roche Diagnostics. Ruedi joined Roche Diagnostics in Basel in 2002 as a Business Development Director. In 2006 he moved to Pleasanton, CA to head the Business Development & Licensing department of Roche Molecular Diagnostics. Then he took over the Life Cycle Leader role of Custom Biotech & Biochemical reagents in 2010 located in Penzberg, Germany. Prior to joining CPS this year in June 2018 as ad-interim Head of Marketing & Business Partnering, Ruedi was leading the Business & Market Development department of Roche Roche Diagnostics Mannheim, Germany.
Prior to joining Roche, Ruedi gained experience in the healthcare sector working for McKinsey & Company located in Zürich, Switzerland. Ruedi is a Swiss citizen and holds a Ph.D. in Cell Biology from the University of Basel, Switzerland, and an MBA degree from Cornell, USA.
Elke Glasmacher academic pursuits span studying Biology in Cologne, specializing in Biochemistry in Boston, and completing her diploma thesis at Munich’s Max Planck Institute of Biochemistry. She pivoted to immunology for her PhD, uncovering key insights into lupus.
In 2010, Glasmacher joined Genentech, discovering significant genomic elements in immune cell differentiation, and later established an independent lab at the Helmholtz Center Munich to explore immune cell fate and activation. Her contributions have been published in top-tier journals like Science and Nature.
From 2017 to 2021, Glasmacher excelled in building and leading the Immune and Cell Biology department at Roche Pharma (pRED), promoting innovation, modern methodologies, and an inclusive environment. Since 2021, she has been the Global Head of Discovery Sciences at Roche, focusing on strategy, governance, and innovation collaborations.
Yaron Daniely is a Partner at aMoon Velocity, aMoon’s early-stage investment fund that pursues disruptive, cutting-edge technologies with the potential to accelerate cure. Yaron also heads aMoon alpha, aMoon’s portfolio success and value creation team.
Yaron has spent much of his career leading innovative HealthTech companies, and he brings to aMoon a wealth of hands-on experience as a business leader in both the private and public sectors.
Prior to aMoon, Yaron was the President and CEO of Yissum, Hebrew University’s acclaimed Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network (ITTN). Before leading Yissum, he spent 14 years as a senior executive – and 10 years as CEO – of private and NASDAQ-traded Biopharma and Biotech companies.
Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, he served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. He also holds an MBA from the Technion – Israel Institute of Technology.
Roy is a Managing Director at aMoon Velocity, where he leads deal teams, manages sourcing, and serves on the board of several portfolio companies.
Roy has over 15 years of investment experience, first as an M&A and Private Equity lawyer in New York, Hong Kong, and Tel Aviv, and later as a venture capitalist.
Before joining aMoon, Roy was the CEO of Hutchison Kinrot, a leading global incubator and seed investor in water technologies & Cleantech, owned by Hong Kong conglomerate CK Hutchison. He led numerous investments in early-stage Israeli start-ups, serving on the boards of all portfolio companies and guiding them from technological concepts to early commercialization.
Prior to that, Roy was a Partner at the International M&A and Capital Markets department of a leading Israeli law firm and worked at the international law firm Weil Gotshal, where his work included representing large healthcare strategics on various financing and M&A transactions.
Roy holds an LLB from the Hebrew University of Jerusalem, and a dual MPA (Public & Economic Policy) from the London School of Economics and Columbia University. He is a certified lawyer in Israel and New York.
Contact us: [email protected]